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Introduction: Enthesitis-related Arthritis (ERA) is a specific category of juvenile idiopathic
arthritis (JIA) characterized by axial and/or peripheral arthritis, and enthesitis, although
other different extra-articular manifestations may encompass its clinical spectrum.
Materials andMethods: In order to examine if ERA-JIA with extra-articular involvement
may represent a different entity from ERA without extra-articular involvement, we
performed a retrospective, observational, monocentric study, in a cohort of ERA patients
followed between 2001 and September 2020 at the Pediatric Rheumatology Unit of
Meyer Children Hospital of Florence. We analyzed the demographic, clinical, laboratory
and imaging data at the disease onset, as well as after 3, 6, and 12 months follow up.
Results: We have enrolled 53 patients, 33 males. At the time of diagnosis, average
age was 10.9 years, 53 patients had active arthritis and 25 active enthesitis. The
middle foot involvement was present in 20 patients. Twenty-five children achieved clinical
remission on medication. Extra-articular manifestations were observed in 14 patients,
of whom 3 had inflammatory bowel disease, 5 uveitis, one uveitis associated with
Crohn disease, 4 SAPHO syndrome, one celiac disease. The cohort was stratified
according to the presence/absence of extra-articular manifestations. It was observed
that middle foot involvement was more frequent in patients with no extra-articular
manifestations (18/39 vs. 2/14; χ2 = 4.45, p = 0.05). Additionally, patients presenting
extra-articular manifestation needed more frequently (12/14 vs. 21/39, χ2 = 4.45, p
= 0.05), and preciously (months: 3.7 ± 5.4 vs. 16.7 ± 26.5, p = 0.02), treatment
with biologic agents. Finally, these patients achieved belatedly (months: 31.6 ± 32.3
vs. 22.9 ± 18.3, p = 0.01) and less frequently (3/14 vs. 22/39; χ2 = 5.50, p
= 0.03) the clinical remission on medication. Eventually, extra-articular involvement
inversely correlated with the middle-foot arthritis (ρs −0.29, p = 0.03), the chance
to achieve remission on medication (ρs −0.31 e p = 0.02), as well as the chance
to keep overall remission, with and without medication (ρs −0.28, p = 0.04).
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Conclusion: In our cohort, children diagnosed with ERA-JIA at the onset of disease
and then developed extra-articular manifestations show the absence of middle foot
involvement and worse prognosis with an early need for the use of biologic agents, and
overall low chance to achieve remission.
Keywords: enthesitis-related arthritis, extra-articular, midfoot, biologic, sacroiliitis, children, JIA
INTRODUCTION
Enthesitis-related Arthritis (ERA) is one of the more common
types of Juvenile Idiopathic Arthritis (JIA) (1), frequently
affecting males after 6-year-old. In Europe and North America,
ERA comprises almost 10% of JIA cases (2, 3) as opposite to
certain countries in Asia where it represents the most common
JIA subtype (35–40% of JIA patients) (4–7). The main findings
of this particular JIA subtype are axial and/or peripheral arthritis,
inflammatory back pain, enthesitis and a specific association with
the HLA-B27 typing.
While the criteria of International League of Associations for
Rheumatology (ILAR) are most commonly used by pediatric
rheumatologists to classify this entity in children, ERA patients
are often regarded as having an undifferentiated form of
juvenile spondyloarthritis (jSpA) (1, 8). However, as opposite
to ERA, jSpA encompasses differentiated forms such as juvenile
ankylosing spondylitis (jAS), psoriatic arthritis (PsA), reactive
arthritis (ReA) and arthritis associated with inflammatory bowel
disease (IBD), as well (8). Moreover, different extra-articular
manifestations, such as uveitis inflammatory bowel disease,
celiac disease, Synovitis Acne Pustulosis Hyperostosis Osteitis
(SAPHO) syndrome or less common cardiac and/or pulmonary
involvement may encompass jSPA spectrum. Conversely to
other JIA subtypes, uveitis in ERA patients is typically
characterized by an acute, symptomatic onset with red, painful,
and photophobic eye, usually unilateral and frequently recurrent
(9, 10). Inflammatory bowel disease, including Crohn disease,
ulcerative colitis and undifferentiated colitis, occurs in 5–10% of
patients affected by ERA, more frequent in males, at the onset
or during disease course (11). In addition, celiac disease occurs
in 1–8% of patients with ERA (12), while SAPHO syndrome
is an even less frequent complication characterized by axial
involvement along with enthesitis and peripheral arthritis and
typical cutaneous findings (13, 14).
Although uncommon, aortic insufficiency as well as
myocarditis, endocarditis and pericarditis, often with
spontaneous resolution, can occasionally occur in ERA
patients (15–17). Pulmonary involvement, characterized by
diminished chest expansion with decreased vital capacity, are
very rare (18, 19), whilst central nervous system (CNS) diseases
are seldom reported in ERA (19).
In order to define the clinical phenotype of ERA-JIA with
extra-articular features, we enrolled patients affected by ERA and
stratified them by the presence of extra-articular manifestations.
Moreover, to address if ERA-JIAwith extra-articular involvement
may represent a different entity from ERAwithout extra-articular
involvement, we compared the clinical features, laboratory data,
treatment modalities, disease activity and outcome of a pediatric
cohort of ERA-JIA patients.
MATERIALS AND METHODS
We performed a retrospective, observational, monocentric study,
in a cohort of patients affected by ERA and followed between
2001 and September 2020 at the Pediatric Rheumatology Unit of
Meyer Children’s University Hospital in Florence.
All patients fulfilled the International League of Associations
for Rheumatology (ILAR) criteria (1, 20) for the diagnosis of
ERA-JIA. We analyzed the demographic, clinical, laboratory and
imaging data at the disease onset, and thereafter at 3, 6, and
12 months follow up. All data were enrolled in a customized
database, including:
• Demographic variables: (1) gender; (2) age at the onset of
clinical manifestation; (3) age at the diagnosis, entered as the
age the child met the (ILAR) criteria for ERA; (4) history
of HLA-B27-related disease in first-degree relatives, including
ankylosing spondylitis, ERA, inflammatory bowel disease,
reactive arthritis (Reiter’s syndrome), and acute anterior
uveitis. Psoriasis was excluded since is a mandatory exclusion
criterion for ERA diagnosis if present in patient and/or in a
first-degree relatives.
• Clinical variables: (1) disease duration; (2) interval between
disease onset and diagnosis; (3) assessment of the number
and type of affected joints. Active arthritis was defined as
a joint with swelling not caused by bone enlargement, or
limitation of motion in combination with pain or tenderness;
(4) assessment of the number and type of affected enthesis.
Enthesitis was defined as discretely localized tenderness at
the point of insertion of ligaments, tendon, joint capsules, or
fascia to bone (21), and assessed according to the Maastricht
Ankylosing Spondylitis Enthesitis Score (MASES), but
including in additional plantar fascia and calcaneus enthesis
(22); (5) middle foot involvement, mono or bilateral; (6)
inflammatory back pain, defined according to the Assessment
of Spondylarthritis International Society (ASAS), expert
criteria (23), as lumbosacral spinal pain persisting at least
3 months in patients with: age < 40 years, insidious onset,
improvement with exercise, not improved with rest, pain at
night (at least 4 of 5 requirements need to be present) (21, 23);
(7) tenderness of sacroiliac (SI) joints, compression of pelvis,
distraction of the SI joints by Patrick’s test (21, 23); (8) limited
anterior spinal flexion, assessed by the modified Schoeber test
(23); (9) limited lateral spinal flexion, according to the ASAS
expert criteria (23); (10) extra-articular features, at the onset or
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during disease course (range was referred in months): uveitis,
diagnosed by slit lamp examination; inflammatory bowel
disease diagnosed by endoscopy and; celiac disease, diagnosed
by laboratory test (antigliadin antibody, ant-transglutaminasis
antibody detected by Enzyme-linked immunosorbent
assay [ELISA] and anti-endomision antibody detected by
Immunofluorescence [IFI]) and by biopsy of duodenum tract;
SAPHO syndrome was diagnosed by the presence of the key
clinical features; (11) Disease activity measures, according to
the American College of Rheumatology pediatric criteria (24);
(12) Disease remission indices, according to the preliminary
criteria for clinical remission in JIA (25), including no
active entheses.
• Laboratory variables: Hemoglobin value (Hb), erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP),
presence of the HLA-B27 allele, and anti-nuclear antibody
(ANA) positivity.
• Imaging SI assessment: Magnetic resonance imaging (MRI)
study of the SI joints: dynamic contrast-enhancement MRI
before and after administration of contrast medium was
performed as described (26, 27). In all patients MRI images
were obtained with a 1.5 Tesla unit (Philips Intera: Philips,
Eindhovenn, The Netherlands) using a pelvic array body
coil with reg following sequences: semicoronal Short tau
inversion recovery (STIR) sequences, semiaxial Turbo spin
echo (TSE) T1-weighted sequences, semicoronal Spectral
Presaturation with Inversion Recovery (SPIR) T1-weighted
sequences, semiaxial TSE T2-weighted sequences, semicoronal
dynamicc T1fat-saturated (FS), and semiaxial T1 SPIR after
administration of intravenous gadolinium (0.1 mmol/kg).
Assessment of the MRI examinations included a grading of
0–3 (0 normal, 1 minimal, 2 moderate, 3 severe) of the
following findings: erosion, sclerosis (low signal intensity on
T1and/or T1 FS), bone marrow edema (high signal intensity
in STIR), contrast enhancement in the bone and in the
joint space, and joint space narrowing and/or Widening. All
assessment and grading were performed at four anatomical
sites for each SI joint: the sacral and iliac sites of the
cartilaginous and ligamentous portions go the joint. In
addition, gadolinium contrast enhancement was performed
and acute/active sacroiliitis on MRI was defined if bone
marrow edema on STIR or bone marrow osteitis on T1
post-gadolinium was detected and located in subchondral
or periarticular bone marrow (28). Moreover, monolateral
and bilateral sacroiliitis was graded 0–4 corresponding to the
New York criteria, according to Aarhus criteria accepted by
Outcome Measures in Rheumatoid Arthritis Clinical Trials
(OMERACT) Rheumatoid Arthritis Magnetic Resonance
Imaging Scoring System (RAMRIS) (29);
• Therapeutic variables, as therapy administered at onset and
throughout the disease course in terms of Disease-modifying
anti-rheumatic drugs (DMARDs) and/or biologic treatment.
Statistical Analysis
All results were expressed as mean and standard deviation (SD),
or median and range. Mann-Whitney U test, Kruskal-Wallis
test, Wilcoxon signed-rank test for paired samples, chi-square
test (χ2) and Fisher exact test, when appropriate, were used
to compare data. Pearson and Spearman correlation tests
were used to determinate correlation coefficients for different
variables (sex, age at diagnosis, number of active joints at
diagnosis, number of active enthesis at diagnosis, middle foot
involvement, inflammation of SI joints, increased ESR, increased
CRP, ANA positivity, HLA-B27 positivity, DMARDs treatment
and timing of therapy, biologic treatment and timing of therapy,
remission time). Multiple stepwise regression was performed
to determine variables that could correlate independently with
the development of extra-articular involvement and a confirmed
diagnosis of ERA at last available follow-up. The predictors used
in the final model were those showing a significant correlation
in the univariate analysis. Non-parametric tests were used, where
necessary, due to the small size of our groups and to the skewness
of data. A p level < 0.05 was considered statistically significant.
All analyses were performed on SPSS for MAC, version 26.0
(SPSS Inc., Chicago, IL, USA).
RESULTS
Fifty-three children fulfilled the criteria for ERA at the time of
diagnosis and were then enrolled into the study: 33 males and 20
females with a median age at diagnosis of 10.9 years (range 3–16
years). Except for eight patients, all children were Caucasian. This
represents 10% of the total cohort of patients with JIA followed
in our center in the same period.
As regards family history, the presence of an autoimmune
disease (Ankylosing Spondylitis, Rheumatoid Arthritis,
Hashimoto thyroiditis, type 1 Diabetes Mellitus, celiac disease,
vitiligo and inflammatory bowel disease) was described
in 23 subjects (43.4%) of whom five reported multiple
autoimmune disease.
At diagnosis, active arthritis was observed in all 53 children,
whilst enthesitis, SI involvement and the middle foot in 25
(47.2%), 23 (43.3%), and 20 (37.7%) patients, respectively.
Table 1 details the clinical features, laboratory parameters and
therapeutic approaches in our cohort of ERA-JIA patients.
At last available follow-up (median time from disease onset
42 months, range: 4–193), 25 patients (47.2%) reached clinical
remission onmedication after a median time of 14months (range
6–62). Clinical remission on medication lasted for a median time
of 67 months (range 9–142). Fifteen patients (28.3%) reached
clinical remission without medication for a median time of 16
months (range 6–35).
Over the disease course, 14 patients (26.4%) developed extra-
articular manifestations, which were not present at diagnosis
but complained during the clinical course. In particular three
patients had inflammatory bowel disease, one child had acute
anterior uveitis associated to IBD, five patients had uveitis, four
patients had SAPHO syndrome, and one patient had celiac
disease. The mean time between ERA-JIA diagnosis and the
extra-articular manifestation onset was 18.8 months (range 9–
60). In three subjects, extra-articular symptoms (uveitis) were
concomitant at the time of ERA onset and diagnosis. Thus,
once the patients developed a confirmed diagnosis of IBD,
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TABLE 1 | Clinical features, laboratory parameters and therapeutic approaches of
our cohort of diagnosed as ERA-JIA at the onset of disease.






Arthritis at diagnosis 53 39 14
- Symmetrical involvement 18 12 6
- Asimmetrical involvement 35 27 8
- Oligoarticular 33 22 11
- Polyarticular 20 17 3
Enthesitis at diagnosis 24 20 4
- Monolateral involvement 13 12 1
- Bilateral involvement 11 8 3
Number of enthesitis at diagnosis
- One 13 12 1
- Two 8 6 2
- Three 2 1 1
- Four 1 1 -
SI involvement 23 16 7
- Monolateral 18 12 6
- Bilateral 5 4 1
Middle foot involvement 20 18 2
- Monolateral 20 18 2
- Bilateral 7 7 -
Laboratory values
Increased ESR 27 19 8
[mean value ± SD (mm/h)] 37.1 ± 29.6 36.1 ± 30.9 40.1 ± 26.2
Increased CRP 27 20 7
[mean value ± SD (mg/dl)] 2.26 ± 2.9 2.17 ± 3.1 2.51 ± 2.9
Anemia 12 9 3
[Hb mean value ± SD (g/dl)] 10.0 ± 1.4 9.9 ± 1.3 10.3 ± 1.2
ANA positivity 16 11 5
HLA B27 positivity 21 18 3
Therapeutic approach
DMARDs 48 37 11
- Methotrexate 28 37 10
- Sulfasalazine 20 19 1
Biologic agents 33 21 12
- Adalimumab 23 14 9
- Etanercept 8 5 3
- Golimumab 1 1 -
- Abatacept 1 1 -
SI, sacroiliac; ESR, erythrocyte sedimentation rate; CRP, C reactive protein;
Hb, hemoglobin; ANA, antinuclear antibodies; DMARDs, disease modifying
anti-rheumatic drugs.
documented by typical histopathology then that affected patients
have been classified as IBD-associated arthritis. The same for
children at disease onset classified as ERA and later on as SAPHO
syndrome due to the development of additional clinical findings.
Therefore, eight (15%) children did not fulfill anymore the
ERA diagnosis.
Persistent arthritis was the indication for the biologic
treatment, along with the development of uveitis, IBD and
SAPHO syndrome in the cohort who exhibited over the disease
course extra-articular involvement. Among these 14 children,
two children, one with coeliac disease and one with uveitis, did
not receive biologic treatment.
Moreover, of the 23 patients affected by sacroiliitis in
ERA, 13 patients were in treatment with DMARDs (12 with
sulphasalazine and 1 with Methotrexate), while 10 patients were
in treatment with anti-TNF alpha inhibitors. Of these 10 patients,
7 developed extra-articular manifestation. In particular: two
patients developed acute anterior uveitis, one patient developed
gastrointestinal involvement, one patient developed celiac disease
and three patients developed SAPHO syndrome. Eventually,
among 23 children with sacroiliitis, 4 out of 23 (17%) did not
fulfill anymore the ERA diagnosis.
Patients’ stratification according to the presence/absence of
extra-articular manifestations revealed that the middle foot
involvement was more frequent in patients without extra-
articular manifestations (18/39 vs. 2/14; χ2 = 4.45, p = 0.05).
Additionally, patients presenting extra-articular manifestations
needed more frequently (12/14 vs. 21/39, χ2 = 4.45, p = 0.05),
and preciously (months: 3.7 ± 5.4 vs. 16.7 ± 26.5, p = 0.02),
treatment with biologic agents (Figure 1). Moreover, this group
of patients achieved less frequently (3/14 vs. 22/39; χ2 = 5.50,
p = 0.03) and belatedly (months: 31.6 ± 32.3 vs. 22.9 ± 18.3, p
= 0.01) the clinical remission on medication (Figure 2). Overall,
considering all the children on clinical remission at last available
follow-up, including patients receiving and stopped treatment,
this group of patients had less chance tomaintain remission (4/14
vs. 26/39: χ2 = 6.08, p= 0.01) (Table 2).
Eventually, extra-articular involvement inversely correlated
with the middle-foot arthritis (ρs −0.29, p = 0.03), the
achievement of remission onmedication (ρs −0.31 e p= 0.02), as
well the chance to keep remission, with and without medication
(ρs −0.28, p= 0.04)
No further correlations considering the number of active
joints, the number of enthesitis, the presence of SI, the
elevation of inflammatory markers, ANA and HLA-B27
positivity, type and duration of treatment with DMARDs
were detected. In multiple regression analysis, where the
development of extra-articular involvement at last available
follow-up was set as dependent variable, the middle foot
involvement and the clinical remission on medication
remained as negative predictors of extra-articular involvement
(multiple R = 0.41, multiple adjusted R2 = 0.14, F: 5.19,
p < 0.009).
Considering that eight children, four with IBDs and four with
SAPHO syndrome, did not fulfill anymore the criteria for ERA-
JIA over the disease course according ILAR classification, we
additionally performed a sub-analysis limited to the 45 ERA-
JIA children who fulfilled the diagnosis of ERA according ILAR
criteria even over the diseases course.
The same statistical significance findings have been detected
regarding the middle foot involvement: it was more frequent in
patients without extra-articular manifestations (18/39 vs. 0/6; χ2
= 4.61, p = 0.03), and extra-articular involvement in ERA-JIA
inversely correlated with the middle-foot arthritis (ρs −0.32, p=
0.03). Conversely, the others statistical significance results have
not been kept.
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FIGURE 1 | Time of Biologic Treatment starting in a cohort of 53 children diagnosed as ERA-JIA at the onset of disease. Figure shows the time from the diagnosis at
biologic treatment starting administration (months) in 12 children with extra-articular involvement, diagnosed ERA-JIA at the onset (white box) and in 21 ERA-JIA
children without extra-articular manifestations (gray box). The central line represents the distribution median, boxes span 25th to 75th percentiles, and error bars
extend from 10th to 90th percentiles. Dots are values higher than the 90th percentile. (p = 0.002). ERA-JIA, enthesitis-related arthritis juvenile idiopathic arthritis.
DISCUSSION
The central pathogenic event in various forms of arthritis in
adults and children alike is certainly chronic inflammation
of the synovial tissue and joint destruction (30, 31). In the
specific types of the arthritis, such as spondyloarthritis in adults
and ERA subtype of JIA in children, other structures, such as
enthesis and/or axial joints, can be affected by inflammation
in similar fashion (11, 32). Finally, the inflammatory process
can spread beyond the musculoskeletal structures throughout
the body causing the various extra-articular manifestations (33).
However, for reasons not entirely clear, this scenario occurs in
less than quarter of patients with SpA (34), while, to the best of
our knowledge, our study was the first to report the incidence
of several extra-articular manifestations in a single cohort of
patients with ERA-JIA.
The results of our study showed that 26% of the enrolled
subjects had and/or developed over the disease course extra-
articular manifestations: three IBD, five uveitis, one uveitis
associated with Crohn disease, four SAPHO syndrome and one
celiac disease.
Therefore, eight children, representing the 15% of this
monocentric cohort, and fulfilling the criteria for ERA at the
onset of disease, developed additional clinical findings and were
then reclassified accordingly: IBD-associated chronic arthritis,
not included in ILAR criteria, and SAPHO syndrome.
In our monocentric cohort, it appears that the current
ILAR criteria failed to properly classify the 15% of patients.
The complexity of childhood rheumatic diseases makes them
difficult to classify in coherent set criteria, as patients may
present simultaneously a various range of manifestations
shared by different disorders or develop over time additional
findings. Mostly in childhood, the phenotype of each patient
may evolve over time and extend beyond defined schemes,
creating overlapping entities challenging to systemize while
relying on the present knowledge (35). Although the ILAR
criteria for ERA-JIA may fit jSpA peculiarities better than
other classifications utilized mainly for adults, in these set
of criteria, jSpA is covered by different subtypes of JIA,
namely psoriatic arthritis, ERA and undifferentiated arthritis
(1). However, certain phenotypes are excluded (e.g., reactive
arthritis, arthritis associated with IBD) and the axial involvement
is not specifically recognize, since the ERA subtype does not
discriminate between axial and peripheral disease. Indeed, how
to categorize JSpA still remains a debated and unsolved issue
(8, 36, 37).
Any attempt to classify SAPHO has been equally difficult,
considering that the articular sings may be the first presentation
of the latter cutaneous findings. While several authors consider
this disorder as a group of autoinflammatory bone disorders
others highlighted the strong link with SpA, especially in later life
stage (38).
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FIGURE 2 | Time to reach clinical remission on medication in a cohort of 53 children diagnosed as ERA-JIA at the onset of disease. Figure shows the time to reach
clinical remission on medication (months) in 3 ERA-JIA children with extra-articular involvement (white box) and in 22 ERA-JIA children without extra-articular
manifestations (gray box). The central line represents the distribution median, boxes span 25th to 75th percentiles, and error bars extend from 10th to 90th
percentiles. Dots are values higher than the 90th percentile. (p = 0.002). ERA-JIA, enthesitis-related arthritis juvenile idiopathic arthritis.















































Since some pathognomonic manifestation often occur late in
disease course, the best chance to properly identify a disease
may be a close clinical monitoring over time and reassessing the
diagnosis when new sings/symptoms appear.
Interestingly, there were several important differences among
patients with and without extra-articular manifestations in our
cohort. Stratifying our cohort according to the presence/absence
of extra-articular manifestations, we identified that the midfoot
involvement in our cohort of ERA-JIA patients seems to correlate
with no extra-articularmanifestations, which was not observed in
previous studies.
However, in accordance with recent literature, the midfoot
involvement seems to be one of the key characteristics of
ERA-JIA and may significantly affect the ERA prognosis.
Phatak et al. (39), in an elegant prospective study, reported
that the midfoot disease produced important functional
limitation. During the course of the last years, numerous
studies addressed the midfoot involvement as characteristic
feature of ERA-JIA (40–42). The inflammation of midfoot
in spondyloarthritis can engage pathological processes such
as tarsal swelling, synovial inflammation, bone overgrowth,
enchondral ossification, enthesophytosis, bone bridging,
and finally ankylosis of the tarsal bones, leading to the
distinctive form of the severe involvement of the feet, named
ankylosing tarsitis (43). Interestingly, the similar changes are
noticed in ankylosing spondylitis (AS), which is considered
the differentiated form of spondyloarthritis, as opposite to the
undifferentiated forms such as ERA-JIA. Therefore, the increased
frequency of midfoot involvement in ERA-JIA patients, that
do not develop extra-articular manifestations, could indicate
the distinctive type of inflammation which spreads mainly
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throughout the musculoskeletal structures, avoiding the other
body systems.
When our analysis was limited to the 45 children who still
meet the ILARA criteria over the disease course, only the middle
foot involvement remained statistically significant related to the
ERA-JIA group with no extra-articular involvement. In our
opinion, this result may strengths the hypothesis that middle foot
involvement strictly belongs to the ERA phenotype, since other
clinical data, even those included into the ILAR criteria were not
able enough to clearly differentiate a group of ERA children, who
at the onset met the ILAR criteria, and were then diagnosed with
another different disease.
Another important finding in our cohort was that ERA-
JIA children that later developed extra-articular manifestations
needed more frequently and preciously treatment with biologic
agents. Moreover, these patients achieved belatedly and less
frequently the clinical remission, on medication as well as
without medication. Therefore, development of a different
disease, such as IBD, as well as a systemic syndrome such as
SAPHO, clearly modifies the prognosis and outcome in these
children initially diagnosed as ERA-JIA according to ILAR
criteria. Clinical experience from adult patients with AS reports
a common association with extra-articular manifestations,
although often subclinical (44). The presence of these comorbid
conditions negatively affects the patients’ quality of life and
overall outcome (45). Emerging knowledge suggests that extra-
articular manifestations in AS may be the expression of a unique
inflammatory process involving the whole body (46). Therefore,
the adoption of a therapeutical strategy that takes into account
patients’ symptoms in their entirety without focusing on a single
area should be considered. In this perspective, an early recourse
to a TNF-inhibitor (adalimumab and infliximab to be preferred
above etanercept) for the management of AS with extra-articular
manifestations and comorbid conditions may represent the most
appropriate therapeutic approach (45–47).
According to several studies, ERA is associated with worse
function, poorer quality of life, and increased pain intensity
(48–50). In particular, HLA-B27 positivity, tarsitis, hip arthritis
within the first 6 months, and older age of disease onset
are associated with worse function, quality of life and pain
(51–53). However, some of these studies reported some
unexpected potential associations. Specifically, it has been
reported that normal ESR correlates with a lower likelihood
of attaining inactive disease (54). Interestingly, the authors
suggested that TNF-alpha inhibitors may be more effective
in patients whose active disease is accompanied by robust
active systemic inflammation mirrored by raised inflammatory
markers. Conversely, disease manifestations, such as joint pain
and enthesalgia, that may not be strongly associated with
systemic inflammation, tend to respond less well to TNF-
alpha inhibitors. In this complicated scenario, non-randomized
studies showed that addingmethotrexate to TNF-alpha inhibitors
seems to be more effective than TNF-alpha inhibitors alone,
which could be explained by different mechanisms of these two
DMARDs (55, 56). Nevertheless, whatever the reason, these
findings are in favor of the concept of the widespread disease in
some patients with ERA-JIA.
We fully acknowledge the limitation of our results imposed
by the small sample size which limits the strength of the
conclusions. However, the present cohort represents the 10%
of all JIA children followed at our unit over the course of 20
years, which is the percentage reported in other cohorts as well
(2, 3).
Additionally, another advocated shortcoming might be that
enthesitis was not confirmed by imaging studies, thus biasing
the ERA-JIA diagnosis at the onset of the disease. However,
none of the enrolled patients has been classified at diagnosis
as ERA-JIA only by the clinical presence of enthesis, without
a concomitant peripheral arthritis. Currently, according ILAR
criteria, confirmation of Enthesitis by imaging is not a
required criterion.
In conclusion, based on clinical observations from our cohort
of patients, we hypothesize that there could be two distinctive
disease phenotypes in JIA children with ERA, depending on
the presence or absence of the extra-articular manifestations.
Specifically, midfoot involvement was associated with ERA-
JIA diagnosis and the absence of extra-articular manifestations.
Conversely, development of extra-articular manifestations over
the time increases the chance of a different disease, such as
Crohn disease and SAPHO syndrome, thus associated with worse
prognosis, an early need for the use of biologic agents, longer time
to achieve remission with and/or without medication. According
to this mono-centric cohort, middle foot involvement seems to
be a specific feature of JIA-ERA, since children with tarsitis,
classified as ERA at the onset, still fulfilled the same criteria over
the course of the disease.
While these findings might already have an important
implication in the diagnostic and therapeutic approach to
JIA patients with ERA, results from a prospective study
involving larger multicenter cohort are mandatory for
their confirmation.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.
ETHICS STATEMENT
Ethical review and approval was not required for the study
on human participants in accordance with the local legislation
and institutional requirements. Written informed consent from
the participants’ legal guardian/next of kin was not required
to participate in this study in accordance with the national
legislation and the institutional requirements.
AUTHOR CONTRIBUTIONS
IP designed the study and drafted the preliminary paper. MS and
EM collected the patients’ data. IM, MM, and LL participated
in drafting the paper. FB helped in imaging assessment. GS
performed statistical analysis, design the study, and finalized
the paper. All authors contributed in writing the papers and
approved the final draft of it.
Frontiers in Medicine | www.frontiersin.org 7 May 2021 | Volume 8 | Article 667305
Pagnini et al. Extra-Articular Involvements in Enthesitis-Related Arthritis
REFERENCES
1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J,
et al. International League of Associations for Rheumatology classification of
juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol.
(2004) 31:390–2.
2. Davies R, Carrasco R, Foster HE, Baildam EM, Chieng SE,
Davidson JE, et al. Treatment prescribing patterns in patients with
juvenile idiopathic arthritis (JIA): analysis from the UK childhood
arthritis prospective study (CAPS). Semin Arthritis Rheum. (2016)
46:190–5. doi: 10.1016/j.semarthrit.2016.06.001
3. Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, et al. The outcomes
of juvenile idiopathic arthritis in children managed with contemporary
treatments: results from the ReACCh-Out cohort. Ann Rheum Dis. (2015)
74:1854–60. doi: 10.1136/annrheumdis-2015-eular.2400
4. Kunjir V, Venugopalan A, Chopra A. Profile of Indian patients with juvenile
onset chronic inflammatory joint disease using the ILAR classification criteria
for JIA: a community-based cohort study. J Rheumatol. (2010) 37:1756–
62. doi: 10.3899/jrheum.090937
5. Shen C-C, Yeh K-W, Ou L-S, Yao T-C, Chen L-C, Huang J-L.
Clinical features of children with juvenile idiopathic arthritis using the
ILAR classification criteria: a community-based cohort study in Taiwan.
J Microbiol Immunol Infect. (2013) 46:288–94. doi: 10.1016/j.jmii.2012.
03.006
6. Arkachaisri T, Tang SP, Daengsuwan T, Phongsamart G, Vilaiyuk
S, Charuvanij S, et al. Paediatric rheumatology clinic population
in Southeast Asia: are we different? Rheumatology. (2017)
56:390–8. doi: 10.1093/rheumatology/kew446
7. Tanya M, Teh KL, Das L, Hoh SF, Gao X, Arkachaisri T. Juvenile idiopathic
arthritis in Southeast Asia: the Singapore experience over two decades. Clin
Rheumatol. (2020) 39:3455–64. doi: 10.1007/s10067-020-05081-9
8. Tse SM, Laxer RM. New advances in juvenile spondyloarthritis. Nat Rev
Rheumatol. (2012) 8:269–79. doi: 10.1038/nrrheum.2012.37
9. Foeldvari I. Ocular involvement in juvenile idiopathic arthritis:
classification and treatment. Clin Rev Allergy Immunol. (2015)
49:271–7. doi: 10.1007/s12016-014-8436-9
10. Monnet D, Breban M, Hudry C, Dougados M, Brézin AP. Ophthalmic
findings and frequency of extraocular manifestations in patients with
HLA-B27 uveitis: a study of 175 cases. Ophthalmology. (2004) 111:802–
9. doi: 10.1016/j.ophtha.2003.07.011
11. Picco P, Gattorno M, Marchese N, Vignola S, Sormani MP, Barabino A, et al.
Increased gut permeability in juvenile chronic arthritides. A multivariate
analysis of the diagnostic parameters. Clin Exp Rheumatol. (2000) 18:773–8.
12. Öman A, Hansson T, Carlsson M, Berntson L. Evaluation of screening for
coeliac disease in children with juvenile idiopathic arthritis. Acta paediatrica.
(2019) 108:688–93. doi: 10.1111/apa.14598
13. Hayem G, Bouchaud-Chabot A, Benali K, Roux S, Palazzo E,
Silbermann-Hoffman O, et al. SAPHO syndrome: a long-term
follow-up study of 120 cases. Semin Arthritis Rheum. (1999)
29:159–71. doi: 10.1016/S0049-0172(99)80027-4
14. Colina M, Govoni M, Orzincolo C, Trotta F. Clinical and
radiologic evolution of synovitis, acne, pustulosis, hyperostosis,
and osteitis syndrome: a single center study of a cohort of 71
subjects. Semin Arthritis Rheum. (2009) 61:813–21. doi: 10.1002/art.
24540
15. Huppertz H, Voigt I, Müller-Scholden J, Sandhage K. Cardiac manifestations
in patients with HLA B27-associated juvenile arthritis. Pediatr Cardiol. (2000)
21:141–7. doi: 10.1007/s002469910023
16. Koca B, Sahin S, Adrovic A, Barut K, Kasapcopur O. Cardiac
involvement in juvenile idiopathic arthritis. Rheumatol Int. (2017)
37:137–42. doi: 10.1007/s00296-016-3534-z
17. Oguz D, Ocal B, Ertan U, Narin H, Karademir S, Senocak F. Left ventricular
diastolic functions in juvenile rheumatoid arthritis. Pediatr Cardiol. (2000)
21:374–7. doi: 10.1007/s002460010084
18. Brambila-Tapia AJ, Rocha-Muñoz AD, Gonzalez-Lopez L, Vázquez-Del-
Mercado M, Salazar-Páramo M, Dávalos-Rodríguez IP, et al. Pulmonary
function in ankylosing spondylitis: association with clinical variables.
Rheumatol Int. (2013) 33:2351–8. doi: 10.1007/s00296-013-2723-2
19. Rodrigues CE, VieiraWP, Bortoluzzo AB, Gonçalves CR, da Silva JA, Ximenes
AC, et al. Low prevalence of renal, cardiac, pulmonary, and neurological extra-
articular clinical manifestations in spondyloarthritis: analysis of the Brazilian
Registry of Spondyloarthritis. Rev Bras Reumatol. (2012) 52:375–83.
20. Fink CW. Proposal for the development of classification criteria for idiopathic
arthritides of childhood. J Rheumatol. (1995) 22:1566–9.
21. Rosenberg AM, Petty RE. A syndrome of seronegative enthesopathy
and arthropathy in children. Arthritis Rheum. (1982) 25:1041–
7. doi: 10.1002/art.1780250902
22. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, Ver
Tempel H, Mielants H, et al. Assessment of enthesitis in ankylosing
spondylitis. Ann Rheum Dis. (2003) 62:127–32. doi: 10.1136/ard.62.2.127
23. Sieper J, van der Heijde D, Landewé R, Brandt J, Burgos-Vagas R, Collantes-
Estevez E, et al. New criteria for inflammatory back pain in patients with
chronic back pain: a real patient exercise by experts from the Assessment
of SpondyloArthritis international Society (ASAS). Ann Rheum Dis. (2009)
68:784–8. doi: 10.1136/ard.2008.101501
24. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A.
Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum.
(1997) 40:1202–9.
25. Wallace CA, Ravelli A, Huang B, Giannini EH. Preliminary validation of
clinical remission criteria using the OMERACT filter for select categories of
juvenile idiopathic arthritis. J Rheumatol. (2006) 33:789–95.
26. Bollow M, Biedermann T, Kannenberg J, Paris S, Schauer-Petrowski
C, Minden K, et al. Use of dynamic magnetic resonance imaging to
detect sacroiliitis in HLA-B27 positive and negative children with juvenile
arthritides. J Rheumatol. (1998) 25:556–64. doi: 10.1007/s002560050446
27. Bollow M, Braun J, Hamm B, Eggens U, Schilling A, König H, et al.
Early sacroiliitis in patients with spondyloarthropathy: evaluation with
dynamic gadolinium-enhanced MR imaging. Radiology. (1995) 194:529–
36. doi: 10.1148/radiology.194.2.7824736
28. Rudwaleit M, Jurik AG, Hermann K-GA, Landewé R, van der Heijde D,
Baraliakos X, et al. Defining active sacroiliitis on magnetic resonance imaging
(MRI) for classification of axial spondyloarthritis: a consensual approach
by the ASAS/OMERACT MRI group. Ann Rheum Dis. (2009) 68:1520–
7. doi: 10.1136/ard.2009.110767
29. van der Heijde DM, Landewé RB, Hermann K-GA, Jurik A-G, Maksymowych
WP, Rudwaleit M, et al. Application of the OMERACT filter to scoring
methods for magnetic resonance imaging of the sacroiliac joints and the
spine. Recommendations for a research agenda at OMERACT 7. J Rheumatol.
(2005) 32:2042–7.
30. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. (2016)
388:2023–38. doi: 10.1016/S0140-6736(16)30173-8
31. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. (2011)
377:2138–49. doi: 10.1016/S0140-6736(11)60244-4
32. Tam L-S, Gu J, Yu D. Pathogenesis of ankylosing spondylitis. Nat Rev
Rheumatol. (2010) 6:399–405. doi: 10.1038/nrrheum.2010.79
33. Brophy S, Calin A. Ankylosing spondylitis: interaction between genes, joints,
age at onset, and disease expression. J Rheumatol. (2001) 28:2283–8.
34. Bengtsson K, Forsblad-d’Elia H, Deminger A, Klingberg E, Dehlin M,
Exarchou S, et al. Incidence of extra-articular manifestations in ankylosing
spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results
from a national register-based cohort study. Rheumatology (Oxford). (2020).
doi: 10.1093/rheumatology/keaa692. [Epub ahead of print].
35. Maniscalco V, Marrani E, Lamot L, Lionetti P, Simonini G. The conundrum
of juvenile spondyloarthritis classification: many names for a single disease?
Lesson learned from an instructive clinical case. Int J Rheum Dis. (2020)
23:1248–51. doi: 10.1111/1756-185X.13922
36. Colbert RA. Classification of juvenile spondyloarthritis: enthesitis-
related arthritis and beyond. Nat Rev Rheumatol. (2010)
6:477–85. doi: 10.1038/nrrheum.2010.103
37. Adrovic A, Sezen M, Barut K, Sahin S, Acikel C, Demirkaya E, et al.
The performance of classification criteria for juvenile spondyloarthropathies.
Rheumatol Int. (2017) 37:2013–8. doi: 10.1007/s00296-017-3837-8
38. Hofmann SR, Kapplusch F, Girschick HJ, Morbach H, Pablik J,
Ferguson PJ, et al. Chronic Recurrent multifocal osteomyelitis (CRMO):
presentation, pathogenesis, and treatment. Curr Osteoporos Rep. (2017)
15:542–54. doi: 10.1007/s11914-017-0405-9
Frontiers in Medicine | www.frontiersin.org 8 May 2021 | Volume 8 | Article 667305
Pagnini et al. Extra-Articular Involvements in Enthesitis-Related Arthritis
39. Phatak S, Mohindra N, Zanwar A, Aggarwal A. Prominent
midfoot involvement in children with enthesitis-related arthritis
category of juvenile idiopathic arthritis. Clin Rheumatol. (2017)
36:1737–45. doi: 10.1007/s10067-017-3733-3
40. Burgos-Vargas R, Pacheco-Tena C, Vázquez-Mellado J. A short-term follow-
up of enthesitis and arthritis in the active phase of juvenile onset
spondyloarthropathies. Clin Exp Rheumatol. (2002) 20:727–31.
41. Adrovic A, Barut K, Sahin S, Kasapcopur O. Juvenile spondyloarthropathies.
Curr Rheumatol Rep. (2016) 18:55. doi: 10.1007/s11926-016-0603-y
42. Aquino MR, Tse SM, Gupta S, Rachlis AC, Stimec J. Whole-body MRI of
juvenile spondyloarthritis: protocols and pictorial review of characteristic
patterns. Pediatr Radiol. (2015) 45:754–62. doi: 10.1007/s00247-015-3319-7
43. Pacheco-Tena C, Pérez-Tamayo R, Pineda C, González-Chávez SA,
Quiñonez-Flores C, Ugalde Vitelly A, et al. Bone lineage proteins in the
entheses of themidfoot in patients with spondyloarthritis. J Rheumatol. (2015)
42:630–7. doi: 10.3899/jrheum.140218
44. Vander Cruyssen B, Ribbens C, Boonen A, Mielants H, Vlam K de, Lenaerts
J, et al. The epidemiology of ankylosing spondylitis and the commencement
of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis. (2007)
66:1072–7. doi: 10.1136/ard.2006.064543
45. Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P,
et al. Treating spondyloarthritis, including ankylosing spondylitis and
psoriatic arthritis, to target: recommendations of an international task
force. Ann Rheum Dis. (2014) 73:6–16. doi: 10.1136/annrheumdis-2013-2
03419
46. Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis
and extra-articular manifestations in everyday rheumatology practice.
Rheumatology. (2009) 48:1029–35. doi: 10.1093/rheumatology/
kep146
47. van den Bosch F. A survey of European and Canadian rheumatologists
regarding the treatment of patients with ankylosing spondylitis
and extra-articular manifestations. Clin Rheumatol. (2010)
29:281–8. doi: 10.1007/s10067-009-1317-6
48. Weiß A, Minden K, Listing J, Foeldvari I, Sieper J, Rudwaleit
M. Course of patients with juvenile spondyloarthritis during 4
years of observation, juvenile part of GESPIC. RMD Open. (2017)
3:e000366. doi: 10.1136/rmdopen-2016-000366
49. Flatø B, Hoffmann-Vold A-M, Reiff A, Førre Ø, Lien G, Vinje O. Long-term
outcome and prognostic factors in enthesitis-related arthritis: a case-control
study. Arthritis Rheum. (2006) 54:3573–82. doi: 10.1002/art.22181
50. Minden K, Niewerth M, Listing J, Biedermann T, Bollow M, Schöntube
M, et al. Long-term outcome in patients with juvenile idiopathic arthritis.
Arthritis Rheum. (2002) 46:2392–401. doi: 10.1002/art.10444
51. Gmuca S, Weiss PF. Evaluation and treatment of childhood enthesitis-
related arthritis. Curr Treat Options Rheumatol. (2015) 1:350–64.
doi: 10.1007/s40674-015-0027-2
52. Weiss PF. Diagnosis and treatment of enthesitis-related arthritis. Adolesc
Health Med Ther. (2012) 2012:67–74. doi: 10.2147/AHMT.S25872
53. Weiss PF. Evaluation and treatment of enthesitis-related arthritis. Curr Med
Lit Rheumatol. (2013) 32:33–41.
54. Donnithorne KJ, Cron RQ, Beukelman T. Attainment of inactive disease
status following initiation of TNF-α inhibitor therapy for juvenile idiopathic
arthritis: enthesitis-related arthritis predicts persistent active disease. J
Rheumatol. (2011) 38:2675–81. doi: 10.3899/jrheum.110427
55. Horneff G, Bock F de, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al.
Safety and efficacy of combination of etanercept and methotrexate compared
to treatment with etanercept only in patients with juvenile idiopathic arthritis
(JIA): preliminary data from the German JIA Registry.Ann RheumDis. (2009)
68:519–25. doi: 10.1136/ard.2007.087593
56. Papsdorf V, Horneff G. Complete control of disease activity and remission
induced by treatment with etanercept in juvenile idiopathic arthritis.
Rheumatology. (2011) 50:214–21. doi: 10.1093/rheumatology/keq292
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Pagnini, Scavone, Maccora, Mastrolia, Marrani, Bertini, Lamot
and Simonini. This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Medicine | www.frontiersin.org 9 May 2021 | Volume 8 | Article 667305
